Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition
Development · 2026-04-15 · 153 (8)
DOI: 10.1242/dev.205259 ↗At a glance
Journal article in Development, published online on 2026-04-21. Written by Christina M Piarowski and 9 co-authors. Institution: Department of Cell and Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Major MEDLINE topics: Proto-Oncogene Proteins c-kit, Taste Buds, Protein Kinase Inhibitors, Taste. Cited 1 times so far (Crossref); 115 references. The full text is freely available (open access, CC BY 4.0). Funded by: University of Colorado, NIDCD NIH HHS, NIH HHS.
Abstract (original language)
Taste dysfunction, or dysgeusia, is a common side effect of many cancer drugs. Dysgeusia is often reported by people treated with anti-angiogenic tyrosine kinase inhibitors (TKIs), which inhibit receptor tyrosine kinases (RTKs). However, the mechanisms by which TKIs cause dysgeusia are not understood, as the role of RTKs in adult taste homeostasis is unknown. Here, we find that treating adult mice with the TKI cabozantinib shifts the fate of differentiating functional taste cell subtypes within taste buds. Through behavioral assays, we find this cell fate shift leads to blunted responses to sweet tastants in cabozantinib-treated mice. Finally, we show that inducible knockout of the RTK KIT, which is inhibited by cabozantinib, phenocopies taste cell fate shifts induced by TKI treatment. Our results establish KIT as a regulator of taste cell homeostasis and suggest that KIT inhibition may underlie TKI-induced dysgeusia in humans.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cell and Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Rocky Mountain Taste and Smell Center, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Immunology, University of Washington, Seattle, WA 98109, USA.
- Developing Scholars Internship Program, Graduate Program in Cell Biology, Stem Cells and Development, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
ORCID profiles: Elaine T Lam, Jakob von Moltke, Linda A Barlow
Funding
- University of Colorado
- NIDCD NIH HHS
- NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
- National Institutes of Health
Cite
APA
Piarowski, C. M., Scott, J. K., Wilson, C. E., Lara, H. I., Salcedo, E., Han, A. S., Lam, E. T., Dempsey, P. J., von Moltke, J., & Barlow, L. A. (2026). Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition. Development, 153(8). https://doi.org/10.1242/dev.205259
Vancouver
Piarowski CM, Scott JK, Wilson CE, Lara HI, Salcedo E, Han AS, et al. Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition. Development. 2026;153(8). doi:10.1242/dev.205259
BibTeX
@article{Piarowski2026,
author = {Piarowski, Christina M and Scott, Jennifer K and Wilson, Courtney E and Lara, Heber I and Salcedo, Ernesto and Han, Andrew S and Lam, Elaine T and Dempsey, Peter J and von Moltke, Jakob and Barlow, Linda A},
title = {Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition},
journal = {Development},
year = {2026},
volume = {153},
number = {8},
doi = {10.1242/dev.205259}
}
EUVIMED